Novavax Inc (NVAX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Novavax Inc (NVAX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9911
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Novavax Inc (Novavax) is a clinical-stage biotechnology company that focuses on the discovery, development and commercialization of vaccines to prevent a range of infectious diseases. Its product portfolio includes recombinant nanoparticle vaccines and adjuvants. The company develops vaccines using its proprietary recombinant nanoparticle vaccine technology including virus-like particle technology (VLPs) and matrix technology. Novavax’s clinical product pipeline includes vaccines indicated against respiratory syncytial virus, influenza, Ebola virus, Zika virus and others. The company has a manufacturing facility in Gaithersburg, Maryland and a subsidiary (Novavax AB) in Sweden. Novavax is headquartered in Gaithersburg, Maryland, the US.

Novavax Inc (NVAX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novavax Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Novavax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Novavax Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Novavax Amends Co-Development Agreement With PATH 11
Novavax Enters Into Co-Development Agreement With CPL Biologicals And International Centre for Genetic Engineering and Biotech 13
Equity Offering 14
Novavax Raises USD57.5 Million in Public Offering of Shares 14
Novavax Plans to Raise USD75 Million in Public Offering of Shares 16
Novavax Raises USD201.2 Million in Public Offering of Common Stock 17
Novavax Raises USD115 Million in Public Offering of Shares 19
Novavax Completes Public Offering Of Shares For US$100 Million 21
Novavax Completes Private Placement Of Shares For US$27 Million 22
Novavax Completes Private Placement Of Shares For US$12.2 Million 23
Debt Offering 24
Novavax Announces Exercise of Over-Allotment Option for Private Placement of 3.75% Notes Due 2023 for USD325 Million 24
Acquisition 26
Novavax Completes Acquisition Of 97.4% Interest In Isconova 26
Novavax Inc – Key Competitors 28
Novavax Inc – Key Employees 29
Novavax Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Joint Venture 30
Recent Developments 32
Financial Announcements 32
Nov 07, 2018: Novavax reports third quarter 2018 financial results 32
Aug 08, 2018: Novavax Reports second quarter 2018 financial results 34
May 09, 2018: Novavax Reports First Quarter 2018 Financial Results 36
Mar 14, 2018: Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results 37
Nov 07, 2017: Novavax Reports Third Quarter 2017 Financial Results 40
Aug 08, 2017: Novavax Reports Second Quarter 2017 Financial Results 41
May 08, 2017: Novavax Reports First Quarter 2017 Financial Results 43
Feb 27, 2017: Novavax Reports Fourth Quarter and Year-End 2016 Financial Results 44
Corporate Communications 45
Nov 01, 2018: Novavax appoints Rachel King to Board of Directors 45
Mar 14, 2018: Novavax Promotes John J. Trizzino to Expanded Role as Chief Business Officer and Chief Financial Officer 46
Oct 13, 2017: Novavax Announces Leadership Change 47
May 11, 2017: Novavax Announces the Promotion of Dr. James F. Cummings to Vice President, Clinical Development and Translational Medicine 48
Clinical Trials 49
May 07, 2018: Novavax Reaches Significant Enrollment Milestone in the Prepare Phase 3 Trial of its RSV F Vaccine 49
Apr 02, 2018: Novavax to Present Clinical Data of RSV F Vaccine at World Vaccine Congress 50
Jul 24, 2017: Novavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs 51
Jul 17, 2017: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM 52
Jun 07, 2017: Novavax RSV F Vaccine Phase 2 Clinical Trial Data in Women of Child Bearing Age Published in Vaccine 53
Jan 19, 2017: Novavax Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Novavax Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novavax Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novavax Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Novavax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Novavax Amends Co-Development Agreement With PATH 11
Novavax Enters Into Co-Development Agreement With CPL Biologicals And International Centre for Genetic Engineering and Biotech 13
Novavax Raises USD57.5 Million in Public Offering of Shares 14
Novavax Plans to Raise USD75 Million in Public Offering of Shares 16
Novavax Raises USD201.2 Million in Public Offering of Common Stock 17
Novavax Raises USD115 Million in Public Offering of Shares 19
Novavax Completes Public Offering Of Shares For US$100 Million 21
Novavax Completes Private Placement Of Shares For US$27 Million 22
Novavax Completes Private Placement Of Shares For US$12.2 Million 23
Novavax Announces Exercise of Over-Allotment Option for Private Placement of 3.75% Notes Due 2023 for USD325 Million 24
Novavax Completes Acquisition Of 97.4% Interest In Isconova 26
Novavax Inc, Key Competitors 28
Novavax Inc, Key Employees 29
Novavax Inc, Other Locations 30
Novavax Inc, Subsidiaries 30
Novavax Inc, Joint Venture 30

List of Figures
Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Novavax Inc (NVAX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Huntington Memorial Hospital:企業の戦略的SWOT分析
    Huntington Memorial Hospital - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Banque Internationale à Luxembourg SA:企業の戦略・SWOT・財務情報
    Banque Internationale à Luxembourg SA - Strategy, SWOT and Corporate Finance Report Summary Banque Internationale à Luxembourg SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Enerjisa Enerji AS:電力:M&Aディール及び事業提携情報
    Summary Enerjisa Enerji AS (Enerjisa Enerji) is a power generation company. The company operates in the business of distribution, and sale of electricity. It provides electricity wholesale and retail services, marketing, products and services development, energy management, and energy consultancy se …
  • Central Electricity Generating Co:企業の戦略的SWOT分析
    Central Electricity Generating Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • China High Speed Transmission Equipment Group Co Ltd (658):電力:M&Aディール及び事業提携情報
    Summary China High Speed Transmission Equipment Group Co Ltd (CHSTE), a subsidiary of Five Seasons XVI Ltd, specializes in the production of high-speed and heavy-load transmission equipment. The company carries out research, design, development, manufacture and distribution of a broad range of mecha …
  • Olam International Ltd:戦略・SWOT・企業財務分析
    Olam International Ltd - Strategy, SWOT and Corporate Finance Report Summary Olam International Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Rothschild Bank Ag
    Rothschild Bank Ag - Strategy, SWOT and Corporate Finance Report Summary Rothschild Bank Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Synchronoss Technologies, Inc. (SNCR):企業の戦略的SWOT分析
    Synchronoss Technologies, Inc. (SNCR) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • TPI Composites Inc (TPIC):企業の財務・戦略的SWOT分析
    TPI Composites Inc (TPIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Serum Institute of India Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Serum Institute of India Ltd (Serum Institute) is a biotechnology company that manufactures and markets vaccines and immuno-biologicals. The company offers products such as bacterial vaccines, viral vaccines, recombinant and combination vaccines, polysaccharide conjugate vaccines, meningococ …
  • Lockheed Martin Corp:企業の戦略・SWOT・財務情報
    Lockheed Martin Corp - Strategy, SWOT and Corporate Finance Report Summary Lockheed Martin Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Simons Group Ltd:企業の戦略・SWOT・財務分析
    Simons Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Simons Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • HESTA Super Fund:企業の戦略的SWOT分析
    HESTA Super Fund - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Nigerian National Petroleum Corporation-石油・ガス分野:企業M&A・提携分析
    Summary Nigerian National Petroleum Corporation (NNPC) is a state-owned vertically integrated oil and gas company, which explores for, produces, markets and distributes crude oil, refined petroleum and associated by-products. It operates through a network of refineries that produce products such as …
  • Kenya Electricity Generating Co Ltd (KGEN):電力:M&Aディール及び事業提携情報
    Summary Kenya Electricity Generating Co Ltd (KenGen) is an electricity generation utility. It produces power from hydro, geothermal, thermal, and wind sources. Under power purchase agreements, the company sells power to customers on wholesale basis. Kenya Power and Lighting Company Limited is the au …
  • Ramot:製薬・医療:M&Aディール及び事業提携情報
    Summary Ramot is a business engagement center of Tel Aviv University that offers technology transfer services. The center manages new technologies from university laboratories to the domestic and commercial markets. It also offers services which include research and development programs, securing ap …
  • Samsung Securities Co Ltd (016360):企業の財務・戦略的SWOT分析
    Samsung Securities Co Ltd (016360) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • King Yuan Electronics Co Ltd (2449):企業の財務・戦略的SWOT分析
    King Yuan Electronics Co Ltd (2449) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Nabriva Therapeutics plc (NBRV):企業の財務・戦略的SWOT分析
    Summary Nabriva Therapeutics Plc (Nabriva) is a biopharmaceutical company that researches and develops antibiotics for the treatment of infections. The company offers product candidate such as Xenleta (lefamulin), CONTEPO (fosfomycin), being developed in both intravenous and oral formulations for th …
  • Virgin Active Limited:企業の戦略・SWOT・財務情報
    Virgin Active Limited - Strategy, SWOT and Corporate Finance Report Summary Virgin Active Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆